Picture of Allakos logo

ALLK — Allakos Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-91.43%
3m-93.11%
6m-91.7%
1yr-95.42%
Volume Change (%)
10d/3m-3.26%
Price vs... (%)
52w High-95.43%
50d MA-86.86%
200d MA-91.57%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-37.86%
Return on Equity-46.84%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Allakos EPS forecast chart

Profile Summary

Allakos Inc. is a clinical stage biopharmaceutical company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory and proliferative diseases. Its initial clinical focus is eosinophilic gastritis and/or eosinophilic duodenitis, inflammatory diseases of the gastrointestinal tract. The Company is focused on the development of lirentelimab (AK002) for the treatment of eosinophil and mast cell related diseases. The Company conducts clinical trials for other mast cell and eosinophil driven diseases including chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Its lead compound, AK002, is in clinical development, and its other product candidates are in preclinical development. The Company’s operations are located in Redwood City, California.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
March 9th, 2012
Public Since
July 19th, 2018
No. of Shareholders
43
No. of Employees
167
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
54,313,379

ALLK Share Price Performance

Latest News for ALLK

Upcoming Events for ALLK

Q4 2021 Allakos Inc Earnings Release

Q1 2022 Allakos Inc Earnings Release

Allakos Inc Annual Shareholders Meeting

Similar to ALLK

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

AbSci

us flag iconNASDAQ Global Select Market

Picture of ACADIA Pharmaceuticals logo

ACADIA Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email